Major Completed Programs
In 2007, the Genetic Association Information Network (GAIN) completed an ambitious program to genotype existing research studies in six major common diseases, and combine the results with clinical data to create a significant new resource for genetic researchers. The network’s goal was to help find genetic causes for common diseases, and its initial efforts focused on Attention Deficit Hyperactivity Disorder, diabetic nepropathy in Type I diabetes, major depression, psoriasis, schizophrenia and bipolar disorder.
Launched in 2002 and completed in 2015, the Osteoarthritis Initiative (OAI) represents a collaboration of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA) and the private sector, working together to improve the efficiency of drug development and clinical trials for the treatment of OA.
This program funded innovative research for preventing, detecting, diagnosing, and treating breast cancer. It sought to provide recent discoveries in basic science to women at risk for breast cancer and to those who need treatment.
Reauthorized in September 2007 through the Food and Drug Administration Amendments Act of 2007, the Best Pharmaceuticals for Children Act of 2007 enabled the testing of drugs that are approved for adult use and used to treat children, but have not been tested for treatment of children.
The Observational Medical Outcomes Partnership (OMOP) was a public-private partnership involving the FDA, multiple pharmaceutical companies, and healthcare providers established to inform the appropriate use of observational healthcare databases for studying the effects (risks and benefits) of medical products.
Grand Challenges in Global Health (GCGH) was launched by the Bill & Melinda Gates Foundation in 2003 as a collaboration with the FNIH—and later also with the Wellcome Trust and the Canadian Institute of Health Research—as a major initiative focused on achieving scientific breakthroughs against diseases that kill millions of people each year in the world’s poorest countries.
The Geoffrey Beene Foundation Alzheimer's Initiative (GBFAI) launched the 2013 Geoffrey Beene Global NeuroDiscovery Challenge with the goal to identify male/female differences in the pathogenesis and presentation of Alzheimer's disease.
This project was designed to improve patient diagnosis and treatment by encouraging the development of more advanced medical imaging software tools.
The NIDDK established a multi-center Drug Induced Liver Injury Network (DILIN) in order to develop standardized instruments to identify and fully characterize cases of drug-induced liver injury.